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Relationship Between Hyperacute Blood Pressure and
Outcome After Ischemic Stroke
Data From the VISTA Collaboration
Gillian M. Sare, MRCP; Myzoon Ali, MRes; Ashfaq Shuaib, MD, FRCPC;
Philip M.W. Bath, MD, FRCP; for the VISTA Collaboration
Background and Purpose—High blood pressure (BP) is associated independently with poor outcome after acute ischemic
stroke, although in most analyses “baseline” BP was measured 24 hours or more postictus, and not during the hyperacute
period.
Methods—Analyses included 1722 patients in hyperacute trials (recruitment 8 hours) from the Virtual Stroke
International Stroke Trial Archive (VISTA) Collaboration. Data on BP at enrolment and after 1, 2, 16, 24, 48, and 72
hours, neurological impairment at 7 days (NIHSS), and functional outcome at 90 days (modified Rankin scale) were
assessed using logistic regression models, adjusted for confounding variables; results are for 10-mm Hg change in BP.
Results—Mean time to enrolment was 3.7 hours (range 1.0 to 7.9). High systolic BP (SBP) was significantly associated
with increased neurological impairment (odds ratio, OR 1.06, 95% confidence interval, 95% CI 1.01 to 1.12), and poor
functional outcome; odds ratios for both increased with later BP measurements made at up to 24 hours poststroke.
Smaller (versus larger) declines in SBP over the first 24 hours were significantly associated with poor NIHSS scores
(OR 1.16, 95% CI 1.05 to 1.27) and functional outcome (OR 1.23, 95% CI 1.13 to 1.34). A large variability in SBP was
also associated with poor functional outcome.
Conclusions—High SBP and large variability in SBP in the hyperacute stages of ischemic stroke are associated with
increased neurological impairment and poor functional outcome, as are small falls in SBP over the first 24 hours.
(Stroke. 2009;40:2098-2103.)
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High blood pressure (BP, systolic BP 140 mm Hg asdefined by the World Health Organization) is present in
approximately 80% of patients with acute ischemic stroke.1
Multiple studies have shown that high BP is associated
independently with poor outcome, including both early death,
and late death/dependency.1–3 Importantly, much of the work
examining the relationship between BP and outcome involves
the use of observational (nonrandomized) data from acute
stroke trials, often with BP measured many hours after stroke
onset.1,2 For example, the first International Stroke Trial
(IST) found a “U-shaped” relationship between systolic BP
(measured, on average, 24 hours after stroke) and outcome in
patients with ischemic stroke such that both high and low
systolic BP (SBP) were associated independently with poor
outcome.1 Similarly, data from the Tinzaparin in Acute
Ischemic Stroke Trial (TAIST) showed high baseline BP
(average 24 hours) to be independently associated with poor
outcome.2
In contrast, there are few data examining BP in the
hyperacute stage of stroke. Analysis of the 303 placebo-
treated patients in the ECASS I trial did not find a relationship
between higher systolic BP (measured within 5 hours) and
outcome; of note, patients with a BP 180/110 mm Hg were
excluded from this trial.3 Similarly, the initial BP measure-
ment (within 6 hours) in placebo-controlled patients from the
ECASS II trial was not independently associated with out-
come; however, BP measurements made at subsequent time
points were predictive of poor functional outcome.4 Because
BP falls naturally over the first week after stroke,5,6 it is
possible that the relationship between BP and outcome may
be related to a failure for BP to fall naturally as well as its
magnitude at onset. Other hemodynamic measures may also
be related to outcome, including BP variability,4,8,9 pulse
pressure, mean arterial pressure, pulse pressure index, and
rate pressure product.2
We examined the relationships between BP, variability in
BP, change in BP over the first 24 hours, and other hemody-
namic measures, all recorded in the hyperacute period, and
early and late outcome in ischemic stroke, using data from the
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Virtual Stroke International Stroke Trial Archive (VISTA)
collaboration.7
Methods
Subjects
Data were obtained from patients with hyperacute ischemic stroke
(8 hours) who received placebo treatment in randomized trials
from the VISTA collaboration.7 VISTA is an academic collaboration
that aims to aid the planning of clinical trials by collating and
providing access to a rich resource of existing patient trial data to
perform exploratory analyses. For reasons of confidentiality, the
VISTA collaboration does not share information on the identity or
number of the trials from which the data set derives (http://
www.vista.gla.ac.uk/charter.aspx?sectpub). Trials that have previ-
ously published similar analyses relating BP and outcome were
excluded (eg, ECASS I, ECASS II4,5) to prevent inclusion bias. We
identified placebo-treated patients from VISTA for whom rt-PA was
not administered; where demographic data, blood pressure (BP),
heart rate measures were available, within the first 10 days; and
where impairment (NIH Stroke Scale [NIHSS]) or dependency
(modified Rankin Scale [mRS]) information were available at up to
90 days postenrolment.
Hemodynamic Measurement
Systolic BP (SBP), diastolic BP (DBP), and heart rate (HR) were
measured in all patients at entry into the trial, and then at 1, 2, 16, 24,
48, and 72 hours. Hemodynamic derivatives of BP and HR were
calculated as follows: pulse pressure (PP)SBPDBP; mean arte-
rial pressure (MAP)DBPPP/3; pulse pressure index (PPI)PP/
MAP; and rate pressure product (RPP, a measure of cardiac
workload)SBPHR.8,9
Change in SBP over the first 24 hours was calculated as SBP at
time pointSBP at baseline. BP variability over 24 hours was
assessed as the coefficient of variation in BPSD in SBP/mean SBP,
using BP data over the first 24 hours. Similar calculations were
performed for variation in SBP over 72 hours, and DBP over both 24
and 72 hours.
Outcome Measurements
Neurological impairment was measured in all subjects at 7 days
using the NIHSS. Functional outcome was assessed using the mRS
at 90 days. Outcomes were divided into a dichotomous scale, poor
versus good outcome; NIHSS scale was divided at its median score,
and mRS was divided with scores of 3 to 6 indicating poor outcome,
and 2 good outcome.
Statistical Methods
The relationship between hemodynamic measures and outcomes
were assessed using unadjusted (t test) and adjusted (logistic regres-
sion) models; adjustments were performed using prognostic and
other clinically relevant variables at baseline: age, sex, NIHSS, time
from stroke to treatment, history of hypertension, and use of
antihypertensive treatment within 7 days of stroke. Relationships
involving change in SBP were additionally adjusted for baseline
SBP. Odds ratios (OR) refer to a change in BP by 10 mm Hg.
Significance was taken at P0.05, and standard deviations or 95%
confidence intervals (95% CI) are given. No adjustment for multiple
comparisons. All analyses were performed using SPSS (version 11.0
for Mac).
Results
Subjects
The data set included 1722 patients randomized to placebo
treatment in hyperacute trials of ischemic stroke from the
VISTA collaboration. Baseline characteristics of the patients
are shown in Table 1. The mean time from stroke onset to
enrolment was 3.7 hours (range 1.0 to 7.9) so that BP
measurements at 24 hours occurred approximately 28 hours
postictus. Mean baseline SBP 154.1 mm Hg (SD 26.4, range
86 to 250 mm Hg) and DBP 83.8 mm Hg (SD 16.0, range 38
to 180 mm Hg). BP fell significantly over the first 24 hours:
SBP mean fall 5.1 mm Hg (SD 24.6 mm Hg, P0.0001);
DBP mean fall 3.2 mm Hg (SD 15.7 mm Hg, P0.0001;
Figure 1). The baseline median NIHSS at baseline was 11
(interquartile range, IQR 8 to 17); this improved over the first
7 days to 7 (IQR 3 to 15); hence, a “poor” NIHSS at day 7
was defined as NIHSS 7.
Blood Pressure and Other
Hemodynamic Variables
Mean hemodynamic measurements and unadjusted and ad-
justed OR and 95% CI are shown in Tables 2 (baseline) and
3 (24 hours). The relationship between SBP, DBP, and RPP
and poor early and late outcome over time are shown in
Figure 2. High SBP at baseline was significantly associated
with increased impairment at day 7, and the point estimates
increased with subsequent measurements up to 24 hours. A
similar pattern was seen with SBP and poor functional
Table 1. Baseline Characteristics for 1722 Patients Included
in Analysis
Characteristic No. (%)/Mean (SD)
Age, y 68.9 (12.1)
Male sex 863 (50.1)
History of hypertension 1,260 (73.2)
History of diabetes 431 (25.0)
Previous stroke 384 (22.3)
Previous TIA 182 (10.6)
History of CHF 181 (10.5)
Atrial fibrillation 471 (27.4)
Time from onset to enrolment, hours 3.7 (1.2)
rt-PA treatment 0 (0)
Baseline NIHSS, median and IQR 11 (8–17)
Baseline systolic BP, mm Hg 154.1 (26.4)
Baseline diastolic BP, mm Hg 83.8 (16.0)
Poor early outcome, NIHSSmedian day 7 867 (50.3)
Poor late outcome, mRS 3–6 day 90 994 (57.7)
TIA indicates transient ischemic attack; CHF, congestive cardiac failure; IQR,
interquartile range; BP, blood pressure.
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Figure 1. Systolic and diastolic blood pressure profiles over the
first 72 hours after entry into the trials.
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outcome at day 90. DBP was not consistently associated with
NIHSS score or functional outcome over the measurement
time period and was generally lower in patients who pro-
ceeded to have a poor outcome. MAP, PP, and RPP (Figure
2) followed a similar pattern to SBP.
Blood Pressure Variability
Increased SBP variability over 24 hours (OR 0.01, 95% CI
0.00 to 0.36, P0.01) was significantly associated with poor
late functional outcome after adjustment. In contrast, SBP
variability was not significantly associated with early impair-
ment (OR 0.03, 95% CI 0.00 to 1.91, P0.10); DBP
variability was not related to either early NIHSS score or late
functional outcome.
Change in Systolic Blood Pressure
Early Impairment
Increased impairment (NIHSS 7) at day 7 was significantly
associated with the change in SBP over the first 24 hours (OR
1.16, 95% CI 1.05 to 1.27). Patients with a high NIHSS score
(poor early outcome) at day 7 had a mean change in SBP of
4.0 mm Hg (SD 24.8), whereas those with a lower score had
a larger change in SBP of8.2 mm Hg (SD 24.6; P0.01, t test).
Late Functional Outcome
Similarly, the change in SBP by 24 hours was also signifi-
cantly associated with a poor late functional outcome after
adjustment (OR 1.23, 95% CI 1.13 to 1.34); patients with a
poor late outcome had a mean change in SBP of 4.8 mm Hg
Table 2. Hemodynamic Measures at Baseline and Odds of Impairment (NIH Stroke Scale, NIHSS) at Day 7, and Death
or Dependency (Modified Rankin Scale, mRS) at Day 90
Hemodynamic Measure Mean (SD) Poor Outcome Mean (SD) Good Outcome Unadjusted OR (95% CI) Adjusted OR (95% CI)
Impairment
(day 7, NIHSSmedian)
Systolic BP 155.4 (27.2) 152.9 (25.7) 1.04 (1.00–1.07) 1.06 (1.01–1.12)
Diastolic BP 83.9 (16.9) 83.6 (15.1) 1.01 (0.95–1.07) 1.10 (1.01–1.22)
Mean arterial pressure 107.7 (17.9) 106.7 (16.6) 1.03 (0.98–1.09) 1.12 (1.02–1.22)
Pulse pressure 71.4 (22.9) 69.3 (21.1) 1.05 (1.00–1.09) 1.03 (0.96–1.12)
Rate pressure product 236.0 (31.4) 231.6 (33.6) 1.04 (1.01–1.07) 1.04 (0.99–1.09)
Death or dependency
(day 90, mRS 3–6)
Systolic BP 156.1 (26.3) 151.7 (26.2) 1.06 (1.03–1.11) 1.05 (0.99–1.12)
Diastolic BP 84.1 (16.5) 83.6 (15.2) 1.02 (0.96–1.08) 1.09 (1.00–1.20)
Mean arterial pressure 108.1 (17.4) 106.3 (16.9) 1.06 (1.00–1.12) 1.09 (1.00–1.19)
Pulse pressure 72.0 (22.4) 68.1 (21.1) 1.08 (1.04–1.014) 1.02 (0.95–0.1.09)
Rate pressure product 236.5 (33.1) 230.0 (31.2) 1.06 (1.03–1.09) 1.05 (1.00–1.10)
Odds ratios per 10-mm Hg change in blood pressure.
Adjusted for age, sex, time to enrollment, baseline NIHSS, history of hypertension, use of antihypertensive treatment in the first 7 days. Bold results
P0.05.
Table 3. Hemodynamic Measures at 24 Hours and Odds of Impairment (NIH Stroke Scale, NIHSS) at Day 7, and Death
or Dependency (Modified Rankin Scale, mRS) at Day 90
Hemodynamic Measure Mean (SD) Poor Outcome Mean (SD) Good Outcome Unadjusted OR (95% CI) Adjusted OR (95% CI)
Poor early NIHSS score
(day 7 median)
Systolic BP 151.3 (25.8) 145.8 (22.6) 1.10 (1.05–1.15) 1.17 (1.08–1.27)
Diastolic BP 78.9 (15.9) 79.7 (14.5) 0.96 (0.90–1.04) 1.13 (1.00–1.26)
Mean arterial pressure 103.0 (16.9) 101.7 (15.4) 1.05 (0.98–1.13) 1.19 (1.07–1.34)
Pulse pressure 72.4 (21.9) 66.1 (18.1) 1.17 (1.10–1.24) 1.18 (1.06–1.30)
Rate pressure product 230.9 (32.9) 220.2 (27.8) 1.13 (1.08–1.17) 1.16 (1.08–1.24)
Poor late outcome
(mRS day 90 3–6)
Systolic BP 151.5 (54.9) 143.9 (22.5) 1.14 (1.09–1.19) 1.17 (1.07–1.27)
Diastolic BP 79.3 (15.9) 79.6 (14.1) 0.99 (0.92–1.06) 1.17 (1.04–1.32)
Mean arterial pressure 103.4 (16.7) 101.1 (15.1) 1.09 (1.02–1.17) 1.24 (1.10–1.38)
Pulse pressure 70.6 (19.5) 64.3 (18.0) 1.021 (1.015–1.31) 1.18 (1.07–1.31)
Rate pressure product 230.1 (31.7) 218.1 (27.6) 1.15 (1.10–1.019) 1.18 (1.10–1.27)
Odds ratios per 10-mm Hg change in blood pressure.
Adjusted for age, sex, time to enrollment, baseline NIHSS, history of hypertension, antihypertensive treatment in the first 7 days. Bold results
P0.05.
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(SD 24.4), whereas those with a good late outcome had a higher
mean change in SBP 8.5 mm Hg (SD 25.1; P0.02, t test).
The proportions of patients with poor early NIHSS scores,
or late functional outcome, by different categories of absolute
change in SBP are shown in Figure 3. Patients with a very large
fall (75 mm Hg) or a large rise in (25 mm Hg) in SBP
appeared to have a worse outcome than those with a moderate
fall; however, the small number of patients with large changes in
SBP means the confidence intervals wide are wide.
The Effect of Antihypertensive Medication
532 (31%) patients received antihypertensive intervention
during the first 7 days after enrolment and these had a higher
BP at baseline: 159.8 (25.8) mm Hg versus 154.6
(26.7) mm Hg (P0.001). By 72 hours, there was no differ-
ence in SBP: 149.6 (21.1) mm Hg versus 151.9 (24.3) mm Hg
(P0.17). Information on the specific agent and timing of
administration were not available.
The use of antihypertensive therapy was associated, in an
unadjusted model, with a significantly reduced risk of high
NIHSS score at day 7 (OR 0.76, 95% CI 0.59 to 0.97); there
was no significant relationship with functional outcome at
day 90 (OR 0.87, 95% CI 0.68 to 1.12). After adjustment for
important covariates, neither outcome was significantly asso-
ciated with use of antihypertensive treatment during the first
7 days (poor NIHSS score OR 0.84, 95% CI 0.61 to 1.15;
poor functional outcome OR 1.04, 95% CI 0.77 to 1.42).
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Figure 2. Figure showing log odds ratios (OR) at measurement time points with 95% confidence intervals (CI) for systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), and rate pressure product (RPP). Values 0 represent an increased risk of early neurologi-
cal impairment (NIHSS 7 at 7 days) or poor late functional outcome (mRS 3 at 90 days).
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Discussion
This analysis of the VISTA database demonstrates that
elevations in systolic blood pressure, mean arterial pressure,
pulse pressure, and rate-pressure product are each associated
with poor outcome in patients with hyperacute ischemic
stroke. These findings support earlier studies where BP
measurements were measured at an average of 24 hours after
stroke onset.1,2 A new finding is that the strength of these
associations appears to increase over the first 24 hours of the
acute stroke phase. Higher DBP was not related to poor
outcome, an unsurprising finding because DBP is less rele-
vant clinically in older patients. In addition to these conven-
tional hemodynamic measures, the magnitude of change in
BP during the first day after stroke onset was also signifi-
cantly associated with poor early NIHSS score and late
functional outcome. In particular, patients having large falls
in BP (75 mm Hg) or rises (25 mm Hg) in the first 24
hours appeared to have the highest risk of a poor outcome, a
finding also seen in the Blood pressure in Acute Stroke
Collaboration10 (Bath P, personal communication).
BP is elevated poststroke in the majority of patients.1 The
present analysis suggests that the strong association between
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Figure 3. Histogram showing the proportion (as percentage and 95% CI) of patients with (A) early neurological impairment (NIHSS
score 7 at 7 days) and (B) poor late functional outcome (mRS 3 at 90 days), by absolute change in systolic blood pressure in the
first 24 hours.
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baseline BP and outcome1,2 reflects both the level of BP and
its rate of fall. Patients in this analysis were not markedly
hypertensive at baseline (mean SBP was 154 mm Hg),
revealing that the failure of BP to fall naturally may be
present in patients with mild as well severe hypertension.
The mechanisms which determine how and when BP falls
during the acute phase are unclear but are likely to relate, at least
in part, to the cause(s) for the initial rise in BP. Transient causes
of hypertension such as the stress of hospitalization and pain (eg,
urinary tract)11 presumably allow high BP to resolve quickly in
parallel with the stimulus; in contrast, those causes which are
sustained over several days, such as the Cushing reflex which
follows intracranial hypertension secondary to cerebral edema,
will drive BP to stay elevated for many hours or days.
This analysis also found a significant association between
SBP variability and poor late functional outcome, a finding
that supports, using a much larger dataset, earlier stud-
ies.3,12,13 Cerebral autoregulation is dysfunctional in acute
stroke so cerebral perfusion could become dependent on BP.
Interestingly, static changes in BP (such as those seen with
antihypertensive induced reductions) may have less effect on
cerebral perfusion than dynamic changes.14
Possible mechanisms for the independent association be-
tween high BP and poor outcome in ischemic stroke include
increased recurrence and cerebral edema1,3; although animal
models have shown an increased risk of hemorrhagic trans-
formation with hypertension,13–15 this has not been shown in
humans in the absence of thrombolysis.1,16 These relation-
ships, and the finding that a slow reduction in raised BP is
also associated with a poor outcome, suggest that trials of BP
lowering need to test a wide time-window, both hyperacutely
to assess potential effects on the index stroke and its penum-
bra, and later during the acute phase to determine effects on
the rate of fall in BP, variability in BP, stroke recurrence and
the development of cerebral edema.
This analysis has several caveats and limitations. First, the
data are taken from placebo-treated patients in various hy-
peracute stroke trials; performing “observational” analysis on
data from randomized controlled trials has the disadvantage
that patients are selected according to predefined inclusion
criteria, thus the results might not be applicable to a more
unselected population of patients. Because the VISTA col-
laboration does not share the identity of the trials,7 we cannot
be certain what particular inclusion criteria were used to
select patients. However, the heterogeneity between trials in
the inclusion/exclusion means the results are more likely to
have external validity. Second, this analysis is tertiary (retro-
spective), although the data were collected prospectively
from high-fidelity trials. Third, a substantial number of
patients received nonrandomized antihypertensive medica-
tion in the first 7 days after enrolment. Treated patients were
more likely to be hypertensive at baseline than those not so
treated. Fourth, the methodology for measuring BP is not
available. Finally, the data set lacks information on stroke
subtype (anterior or posterior circulation; large or small
vessel) and therefore lacks the sensitivity to detect whether
individual subgroups respond differently to BP.
This analysis provides important novel information on the
effect of raised BP in the hyperacute phase of stroke on outcome.
High BP, other hemodynamic variables, increased variability in
BP, and failure for BP to fall rapidly were each related to poor
outcome. Ongoing randomized trials into the effect of antihy-
pertensive treatment in acute stroke (ENOS,15 INTERACT, and
SCAST) may help to answer questions about the timing of
intervention and the magnitude of BP reduction.
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